Fluorouracil 50 mg/mL - otsingu tulemused

fluorouracil mylan 50mg per ml 20ml vial

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - fluorouracil - solution for infusion or injection - fluorouracil 50 mg/ml - antineoplastic agents

Malta - inglise - Medicines Authority

fluorouracil mylan 50mg per ml 50ml vial

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - fluorouracil - solution for infusion or injection - fluorouracil 50 mg/ml - antineoplastic agents

Malta - inglise - Medicines Authority

fluorouracil mylan 50mg per ml 100ml vial

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - fluorouracil - solution for infusion or injection - fluorouracil 50 mg/ml - antineoplastic agents

Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

dbl™ fluorouracil

pfizer new zealand limited - fluorouracil 25 mg/ml; ; - solution for injection - 25 mg/ml - active: fluorouracil 25 mg/ml - dbl® fluorouracil injection b.p. is indicated alone or in combination for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas. fluorouracil should only be used when other proven measures have failed or are considered impractical.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

fluorouracil injection, solution

bluepoint laboratories - fluorouracil (unii: u3p01618rt) (fluorouracil - unii:u3p01618rt) - fluorouracil 50 mg in 1 ml - fluorouracil is indicated for the treatment of patients with: none. pregnancy category d risk summary there are no adequate and well-controlled studies with fluorouracil in pregnant women. based on its mechanism of action, fluorouracil can cause fetal harm when administered to a pregnant woman. administration of fluorouracil to rats and mice during selected periods of organogenesis, at doses lower than a human dose of 12 mg/kg, caused embryolethality and teratogenicity. malformations included cleft palate and skeletal defects. in monkeys, maternal doses of fluorouracil higher than an approximate human dose of 12 mg/kg resulted in abortion. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to a fetus [see clinical pharmacology (12.1)] . animal data malformations including cleft palate, skeletal defects and deformed appendages (paws and tails) were observed when fluorouracil was administered by intraperitoneal injection